Teva to acquire Actavis business for US$40.5bn

27 July 2015 - Deborah Wilkes

Archived

Teva is set to acquire Allergan's Actavis generics business – including the international OTC unit – in a cash and shares deal worth US$40.5 billion. Teva has now abandoned its hostile takeover bid for generics company Mylan.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: